跳至主要内容
临床试验/NCT01543542
NCT01543542已完成2 期

A Phase II Multi-institutional Study Assessing Simultaneous In-Field Boost Helical Tomotherapy for 1-3 Brain Metastases

Lawson Health Research Institute5 个研究点 分布在 1 个国家目标入组 91 人开始时间: 2010年4月1日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
已完成
入组人数
91
试验地点
5
主要终点
Overall survival

研究概览

简要总结

Helical tomotherapy is a novel radiation treatment machine that combines two existing technologies: spiral radiotherapy treatments combined with simultaneous computed tomotherapy imaging of the body. This new machine can potentially allow radiation treatments to be focused more precisely, and delivered more accurately than with existing radiation machines. In this study, helical tomotherapy will be used to provide radiation treatments (whole brain radiotherapy, daily over 10 treatments) that are commonly used to treat cancer metastatic to the brain. In addition, the individual spots of cancer (metastases) in the brain will be treated to a higher dose (approximately 2 times higher) than the dose to the whole brain. The purpose of this study is to determine the effectiveness of whole brain radiation with lesion boosting with the helical tomotherapy machine.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Histological diagnosis of primary cancer
  • •Contrast enhanced MRI demonstrating 1-3 metastases within 6 weeks of enrollment
  • •Age greater than or equal to 18
  • •Karnofsky performance status greater than or equal to 70
  • •Patient available for subsequent follow-up appointments and testing as well as health-related quality of life questionnaires
  • •Anticipated survival (independent of the brain metastases) greater than 3 months
  • •Patient informed consent obtained
  • •Metastatic suitable for synchronous boost
  • •Extracranial disease controlled or to be treated

排除标准

  • •Underlying medical condition precluding adequate follow-up
  • •Prior cranial radiotherapy
  • •Concurrent cytotoxic chemotherapy

研究组 & 干预措施

Radiation Therapy Treatment

Other

Whole Brain XRT 30Gy/10 fractions with Simultaneous Infield Boost of Brain Lesions to 60Gy

干预措施: Whole Brain XRT 30Gy/10 fractions with (Radiation)

结局指标

主要结局

Overall survival

时间窗: At approximately end of year 4 (study completion)

Local disease control rate at 6 months

时间窗: At approximately 2.5 years

CNS disease control rate at 6 months

时间窗: At approximately 2.5 years

次要结局

  • Acute toxicity(At approximately end of year 4 (study completion))
  • Assessment of RTOG versus RECIST versus Volumetric MRI criteria(At approximately end of year 4 (study completion))
  • Health related quality of life(At approximately end of year 4 (study completion))
  • Karnofsky performance status(AT approximately end of year 4 (study completion))
  • Mini mental status exam cognition(At approximately end of year 4 (study completion))
  • Late toxicity(At approximately end of year 4 (study completion))
  • Changes in MRI endpoints(Measured at baseline, and 3 months and 6 months post-treatment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

George Rodrigues

Principal Investigator

Lawson Health Research Institute

研究点 (5)

Loading locations...

相似试验